Nigeria: Nigerian Drugmaker Fidson Selected to Manufacture Generic Influenza Antiviral Under Global Licence
[Premium Times] The selected manufacturers are from Brazil, China, India, Indonesia, Malaysia, Nigeria, Uganda, Ukraine and Vietnam.
Nigerian pharmaceutical company Fidson Healthcare Plc has been selected to manufacture a generic version of baloxavir marboxil, an antiviral medicine used to treat influenza. This selection makes Fidson one of 11 manufacturers across nine countries chosen under a voluntary licensing agreement between the Medicines Patent Pool (MPP) and Swiss pharmaceutical company Roche.
The MPP, a United Nations-backed public health organisation, selected manufacturers from Brazil, China, India, Indonesia, Malaysia, Nigeria, Uganda, Ukraine, and Vietnam to diversify supply pathways for influenza treatment, support regional production, and strengthen preparedness for future outbreaks and pandemics.
Brief written by urgent.news from AllAfrica Health's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
